Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
Airbus Spain Workers Approve Deal to End Months of Strikes 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Circle Urges EU to Revise MiCA Stablecoin Rules 
WordPress Malware Uses Ethereum to Evade Removal 
Add as a preferred source on Google
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 8, 2017 at 8:40 a.m. EST.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
